ArticleJTO clinical and research reports2024

Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment.

Sabine Schmid et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.